Page 67 - Read Online

Feusier et al. J Transl Genet Genom 2021;5:189-99 https://dx.doi.org/10.20517/jtgg.2021.05 Page 197

Reviewed and edited the manuscript: Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B,
Osman AEG, Glenn MJ, Camp NJ

Availability of data and materials
The Shared Genome Segment (SGS) analysis software is freely available and can be accessed online:
https://uofuhealth.utah.edu/huntsman/labs/camp/analysis-tool/shared-genomic-segment.php. Data used in
the SGS analysis includes pedigree structures, CLL diagnoses, and genome-wide SNP genotypes. Pedigree
structures necessary for these analyses were acquired from the UPDB. These are considered potentially
identifiable by the Resource for Genetic and Epidemiologic Research (RGE) - the ethical oversight
committee for the UPDB. As a result, access to these data requires review by the RGE committee (contact
Jahn Barlow, jahn.barlow@utah.edu). Upon RGE approval, we will provide the genotypes and pedigree
structure in a format ready to be used by the SGS software.

Financial support and sponsorship
The study was made possible by National Cancer Institute (NCI) R01 CA134674 (to NJC). JF was supported
by the National Center for Advancing Translational Sciences of the National Institutes of Health under
Award Number UL1 TR002538 and TL1 TR002540. This research was supported by the UCR, which is
funded by the NCI's SEER Program, Contract No. HHSN261201800016I, the US Center for Disease Control
and Prevention's National Program of Cancer Registries, Cooperative Agreement No. NU58DP0063200,
with additional support from the University of Utah and Huntsman Cancer Foundation. Partial support for
all datasets within the UPDB is provided by the University of Utah, Huntsman Cancer Institute and the
Huntsman Cancer Institute Cancer Center Support grant, P30 CA42014 from the National Cancer Institute.
The content is solely the responsibility of the authors and does not necessarily represent the official views of
the National Institutes of Health.

Conflicts of interest
Stephens DM has served on advisory boards for Beigene, Jannsen, Pharmacyclics, Epizyme, Adaptive, TG
Therapeutics, Karyopharm, Innate. Stephens DM has received research funding from Karyopharm, Acerta,
Arqule, Mingsight, Juno, Gilead, Verastem. Hu B has received research funding from Miragen, Roche,
CRISPR Therapeutics and Celgene.

Ethical approval and consent to participate
All work was performed under Approved University of Utah IRB protocol 88405. Ethics committees at the
University of Utah approved this research. All participants provided written informed consent.

Consent for publication
Not Applicable.

Copyright
© The Author(s) 2021

REFERENCES
1. Chronic lymphocytic leukemia - Cancer Stat Facts. Available from: https://seer.cancer.gov/statfacts/html/clyl.html. [Last accessed on
21 May 2021].
2. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic
lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004;104:1850-4. DOI PubMed
3. Kerber RA, O'Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer
2005;103:1906-15. DOI PubMed
4. Slager SL, Caporaso NE, de Sanjose S, Goldin LR. Genetic susceptibility to chronic lymphocytic leukemia. Semin Hematol
2013;50:296-302. DOI PubMed PMC
5. Goldin LR, Ishibe N, Sgambati M, et al. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol